194 related articles for article (PubMed ID: 10081908)
1. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
2. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
4. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
[TBL] [Abstract][Full Text] [Related]
5. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.
Kitagawa Y; Kunimi K; Ito H; Sato H; Uchibayashi T; Okada Y; Seiki M; Namiki M
J Urol; 1998 Oct; 160(4):1540-5. PubMed ID: 9751409
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
8. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
10. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
12. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.
Donmez G; Sullu Y; Baris S; Yildiz L; Aydin O; Karagoz F; Kandemir B
Pathol Res Pract; 2009; 205(12):854-7. PubMed ID: 19762163
[TBL] [Abstract][Full Text] [Related]
14. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
17. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
19. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
20. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
